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Abstract: The uninsured population has much to gain from affordable sources of prescription
medications. No prior studies have assessed the prevalence and predictors of low-cost generic drug
programs (LCGP) use in the uninsured population in the United States. A cross-sectional study
was conducted using data from the Medical Expenditure Panel Survey (MEPS) during 2007–2012
including individuals aged 18 and older who were uninsured for the entire 2-year period they were
in MEPS. The proportions of LCGP fills and users was tracked each year and logistic regression
was used to assess significant factors associated with LCGP use. A total of 8.3 million uninsured
individuals were represented by the sample and 39.9% of these used an LCGP. Differences between
users and non-users included higher age, gender, year of participation, and number of medications
filled. The proportion of fills and users via LCGPs increased over the 2007–2012 study period.
Healthcare providers, especially pharmacists, should make uninsured patients aware of this source
of affordable medications.
Keywords: uninsured; generic drugs; low-cost generic; generic drug discount programs;
MEPS; access
1. Introduction
Individuals lacking medical insurance are disproportionately likely to suffer from negative health
outcomes and barriers to health services than individuals with private or public insurance plans [1–6].
Prescription medications can offer a powerful first line of defense against conditions that commonly
lead to costly in-patient hospital admissions, such as infections, heart disease and hypertension.
However, despite their ability to ameliorate both chronic and acute illnesses, the high-cost of
medications often serves as a barrier to access for uninsured individuals [7–10]. Low-cost generic drug
programs (LCGPs) offered by major chain pharmacies improve both the affordability and accessibility
of medications that may be used to treat many common acute and chronic conditions [11,12].
LCGPs first appeared in the United States (U.S.) in mid-2006 with Kmart providing 90 days of
certain generics for $15 and was shortly followed by Wal-Mart’s $4 program [13]. Since then, generic
discount programs are now in place at almost all major pharmacy chains including 8 of the top 10
largest chain pharmacies in the nation and include one-third of the top 100 generics used by Americans
by volume [11,13,14]. These programs include a wide variety of medication categories—cardiovascular,
antibiotics, asthma, analgesics, anti-diabetes, mental health, men’s health, and women’s health, among
others [15–17].
Poor and uninsured individuals arguably have the most to gain from the increased affordability
and accessibility offered by LCGPs. Despite the tremendous impact that LCGPs may have on the
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uninsured population in the U.S., there is a relative dearth of literature assessing the prevalence of
LCGP use in a nationally representative uninsured population. In 2008, over 70 million Americans
were estimated to have used an LCGP to obtain a prescription medication—a figure that has likely
expanded as the number and popularity of these programs has increased [13,17,18]. In this 2008
self-reported survey, one-third of adults and one-quarter of children without insurance coverage
reported using these programs [18]. However, given that self-reported surveys are particularly prone
to recall and selection bias it is difficult to ascertain whether these estimates accurately represent LCGP
use in the uninsured population.
Few studies have assessed the demographic and clinical characteristics of LCGP users and
non-users [19,20] and none to our knowledge have assessed LCGP use specifically in an uninsured
population. Understanding the factors that influence which individuals currently utilize these
programs is a crucial first-step in increasing use amongst patients that have the most to gain from
LCGPs. This study had four objectives: (1) Assess the prevalence of LCGP use in a nationally
representative uninsured population; (2) Compare demographic and clinical characteristics of LCGP
users and non-users; (3) Determine significant predictors of LCGP use; and (4) Analyze trends in LCGP
use amongst uninsured individuals from 2007–2012.
2. Materials and Methods
2.1. Data Source
This study utilized public use data from the Medical Expenditure Panel Survey (MEPS) for
the years 2007–2012. MEPS is a nationally representative survey of civilian, non-institutionalized
individuals in the U.S. and includes information on demographics, healthcare utilization, medical
conditions, and prescription medication use. MEPS uses an overlapping panel design with a new
cohort (“panel”) added each year and participating in the survey for up to two years. Data are collected
in five rounds throughout a panel’s two years of participation. Survey sampling and response weights
are included so that population estimates may be obtained.
2.2. Study Subjects and Design
A cross-sectional study design was used to compare differences between LCGP users and
non-users. Rates of LCGP use from 2007–2012 were quantified to assess trends in the proportions
of LCGP fills and LCGP users over these years. These years were chosen because 2007 was the
first full year in which LCGPs were available and 2012 is the most recent year of data available
from MEPS. Inclusion in the study cohort required that individuals lack medical and pharmacy
health insurance for both years of their MEPS panel, had no third party payers in the MEPS
pharmacy component, participated in all five rounds of data collection, and reported using at least one
prescription medication during their two-year panel period. The final sample was representative of
those who are “long-term uninsured” (i.e., ě2 years) who have filled a prescription.
2.3. Use of Low-Cost Generic Programs
MEPS captures medication fills at the pharmacy level; thus effectively capturing all medication
fills paid by cash. Survey participants are first asked in-person about all medications which are have
been filled. Surveyors obtain pharmacy information from prescription bottles and receive permission
to contact the pharmacies for more information. Once permission is granted, details regarding each
fill for each medication are extracted including name, NDC number, and the amounts paid by the
customer or any third parties.
Four stipulations were used to define LCGP use: (1) The total cost of the drug was paid out of
pocket; (2) The cost of the drug exactly matched the cost of an LCGP drug as reported by pharmacies;
(3) The medication was listed on an LCGP formulary from a major chain pharmacy from 2007–2012;
and (4) Oral medication fills were dispensed for 30 or 90 day supplies of medications, with the
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exception of anti-infectives, contraceptives, and steroids which were allowed to vary given differential
dosing intervals for these classes. LCGP use was coded at the person level as a binary dependent
variable for any use during the study period and at the medication level for each medication fill.
Pharmaceutical utilization was determined for medications available from LCGPs based on Multum
Lexicon classifications (Cerner Multum™, Denver, CO, USA), which is included in the MEPS pharmacy
files for each medication.
2.4. Subject Characteristics
Cohort demographics and characteristics of interest included age, race, gender, family income
level, number of prescriptions filled. For comparison, the cohort was divided by age categories: 0–17,
18–34, 35–54, 55–64, and 65+ years of age. Family income level was based on MEPS classifications
of income levels which are stratified as a percentage of the Federal Poverty Level (FPL): <100%,
100%–125%, 126%–200%, 201%–400%, and >400% of the FPL. Residence within a metropolitan
statistical area (MSA) was recorded as a binary variable and region was categorized by U.S. Census
regions. Race was divided between Whites, Hispanics, African-Americans, Asians, and others. Age,
family income, region, MSA and insurance type were all assessed at the last round of data collection.
A Charlson Comorbidity Index (CCI) score was calculated for each individual based on the algorithm
by Quan et al. [19].
2.5. Data Analysis
The proportions of LCGP uses and users were tracked from 2007 to 2012. These proportions
were compared to overall pharmaceutical utilization for users and non-users over the same time
period. Comparisons were conducted for cohort characteristics of interest between users and non-users
using chi-square or t-tests. Multivariable logistic regression was used to identify factors associated
with LCGP use. Adjusted odds ratios (AOR) and 95% confidence intervals were reported. All data
analyses were conducted using SAS 9.4 [21] (SAS Institute, Cary, NC, USA) implementing SAS
procedures (SURVEYMEANS, SURVEYFREQ, and SURVEYLOGISTIC) that take into account the
complex survey design of MEPS and use the longitudinal survey weights supplied by MEPS to
calculate population estimates over the two-year period. This manuscript was drafted in accordance
with STROBE guidelines for reporting observational studies.
3. Results
3.1. Cohort Comparison
Over the years 2007–2012 a total of 2535 uninsured individuals met all inclusion criteria. Applying
MEPS person weights, this population represents 8,327,690 uninsured individuals annually who filled
a prescription medication—representing approximately one fourth of the U.S. uninsured population
prior to the implementation of the Affordable Care Act. Of this population, 39.9% (N = 3,321,071)
were classified as LCGP users, having filled at least one prescription through an LCGP during their
two-year panel period.
Demographic and clinical comparisons between users and non-users are presented in Table 1.
Significant differences between LCGP users and non-users existed in terms of age, sex, MEPS panel,
number of medications filled, and number of unique medications used. LCGP users were significantly
more likely to be aged 55 or greater than LCGP non-users (19.1% vs. 10.4%). Additionally, a significantly
greater proportion of LCGP users were female than non-users (55.6% vs. 44.7%). In terms of the number
of medications used, LCGP users filled significantly more unique prescriptions and had more total
medication fills than non-users.
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Table 1. Demographic characteristics of study cohort.
LCGP Users Non-Users
N %
N %
N %
N %
(Weighted) (Weighted) (Weighted) (Weighted)
Overall Sample: N = 2535
1023 40.4 3,321,071 39.9 1512 59.6 5,006,619 60.1
Age *
0–17 55 5.4 197,217 5.9 130 8.6 468,222 9.4
18–34 308 30.1 1,097,996 33.1 597 39.5 2,060,812 41.2
35–54 465 45.5 1,461,488 44 637 42.1 1,955,761 39.1
55–64 180 17.6 531,079 16.0 144 9.5 509,644 10.2
65+ 15 1.5 33,290 1.0 4 0.3 12,180 0.2
Sex *
Male 413 40.4 1,473,855 44.4 753 49.8 2,766,344 55.3
Female 610 59.6 1,847,216 55.6 759 50.2 2,240,275 44.7
Race
White 333 32.6 1,762,453 53.1 485 32.1 2,589,120 51.7
Hispanic 441 43.1 919,879 27.7 668 44.2 1,468,093 29.3
Black 187 18.3 429,532 12.9 252 16.7 659,446 13.2
Asian 38 3.7 118,957 3.6 59 3.9 157,624 3.1
Other 24 2.3 90,249 2.7 48 3.6 132,337 2.6
Region
Northeast 70 6.8 270,591 8.1 153 10.1 568,708 11.4
Midwest 161 15.7 598,921 18.0 224 14.8 840,617 16.8
South 540 52.8 1,614,540 48.6 726 48 2,375,859 47.5
West 252 24.6 837,018 25.2 409 27.1 1,221,435 24.4
Income Category
<100% of FPL 305 29.8 930,090 28.0 461 30.5 1,322,446 26.4
100% to 125% of FPL 86 8.4 230,157 6.9 151 10 400,395 8.0
125% to 200% of FPL 252 24.6 728,102 21.9 365 24.1 1,117,602 22.3
200% to 400% of FPL 274 26.8 900,861 27.1 387 25.6 1,396,285 27.9
>400% of FPL 106 10.4 531,861 16.0 148 9.8 769,891 15.4
MSA
Rural 153 15 587,178 17.7 227 15 885,641 17.7
Urban 870 85 2,733,892 82.3 1,285 85 4,120,978 82.3
Marital Status
Not Married 563 55 2,023,346 60.9 909 60.1 3,210,180 64.1
Married 460 45 1,297,725 39.1 603 39.9 1,796,439 35.9
Employment
Unemployed 366 35.8 1,144,601 34.5 547 36.2 1,680,822 33.6
Employed 657 64.2 2,176,469 65.5 965 63.8 3,325,797 66.4
Education
Less than High School 345 33.7 824,719 24.8 520 34.4 1,330,469 26.6
High School or Equivalent 481 47 1,721,585 51.8 668 44.2 2,402,929 48.0
Some College 197 19.3 774,767 23.3 324 21.4 1,273,222 25.4
MEPS Panel (years) *
12 (2007–2008) 109 10.7 469,931 14.1 320 21.2 1,401,201 28
13 (2008–2009) 243 23.8 773,787 23.3 385 25.5 1,062,261 21.2
14 (2009–2010) 199 19.5 614,551 18.5 292 19.3 967,636 19.3
15 (2010–2011) 210 20.5 743,519 22.4 208 13.8 707,594 14.1
16 (2011–2012) 262 25.6 719,283 21.7 307 20.3 867,927 17.3
Delays In Getting Necessary Medications
No Delays 919 89.8 2,918,531 87.9 1421 94 4,638,638 92.7
Delays 104 10.2 402,539 12.1 91 6 367,981 7.3
CCI *
0–1 856 83.7 2,884,043 86.8 1425 94.2 4,736,873 94.6
2–4 160 15.6 424,906 12.8 65 4.3 214,697 4.3
5+ 5 0.5 9106 0.3 4 0.3 9640 0.2
Missing 2 0.2 3016 0.1 18 1.2 45,409 0.9
Total Number of Medication Fills *
Median (IQR) 5 (2–16) 4.9 (1.7–16.6) 2 (1–4) 1.3 (1–3.5)
Unique Medications Used *
Median (IQR) 3 (2–5) 2.1 (1.1–4.2) 1 (1–2) 1 (1–1.8)
* p < 0.001 between group comparison; Percentages not adding to 100% are due to rounding errors;
CCI = Charlson Comorbidity Index; IQR = interquartile range; MSA = metropolitan statistical area; LCGP = low
cost generic program; FPL = federal poverty limit.
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3.2. Predictors of LCGP Use
The full multivariable logistic regression model with adjusted odds ratios and 95% confidence
intervals is presented in Table 2. Significant predictors of LCGP use included MEPS panel number and
number of unique medications used. Participants in Panels 13–16—taking place from 2008–2012—had
greater than double the odds of using an LCGP than individuals in panel 12 (2007–2008). The panel
with the greatest odds of using LCGPs was observed to be panel 15 (2010–2011) with individuals in
this panel being greater than four times more likely to use an LCGP than those in panel 12 (AOR: 4.02
(95% CI: 2.75–5.87)). Additionally, each unique medication used increased the odds of LCGP use by
43% (AOR: 1.43 (95% CI: 1.27–1.62)).
Table 2. Multivariable logistic regression results of predictive characteristics for LCGP use.
Characteristic Adjusted Odds Ratio 95% Wald Confidence Limits
Age Lower Upper
0–17 Ref. Ref. Ref.
18–34 1.12 0.63 2.00
35–54 1.20 0.65 2.22
55–64 1.50 0.75 2.97
65+ 4.02 0.69 23.25
Gender
Male Ref. Ref. Ref.
Female 1.24 0.99 1.56
Marital Status
Not Married Ref. Ref. Ref.
Married 1.00 0.79 1.27
Employment
Unemployed Ref. Ref. Ref.
Employed 0.98 0.75 1.28
Education
Less than High School Ref. Ref. Ref.
High School or Equivalent 1.12 0.85 1.46
Some College 1.08 0.75 1.56
Income Category
<100% of FPL Ref. Ref. Ref.
100% to 125% of FPL 0.79 0.50 1.24
125% to 200% of FPL 0.96 0.73 1.28
200% to 400% of FPL 1.02 0.76 1.37
>400% of FPL 1.05 0.69 1.59
Race
White Ref. Ref. Ref.
Hispanic 1.18 0.89 1.56
Black 0.93 0.67 1.30
Asian 1.36 0.76 2.44
Other 1.18 0.63 2.19
MSA
Rural Ref. Ref. Ref.
Urban 1.11 0.80 1.53
Region
Northeast Ref. Ref. Ref.
Midwest 1.31 0.88 1.93
South 1.27 0.88 1.83
West 1.16 0.79 1.71
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Table 2. Cont.
Characteristic Adjusted Odds Ratio 95% Wald Confidence Limits
Panel Number (years of panel)
12 (2007–2008) Ref. Ref. Ref.
13 (2008–2009) 2.33 1.62 3.36
14 (2009–2010) 2.31 1.63 3.29
15 (2010–2011) 4.02 2.75 5.87
16 (2011–2012) 2.78 1.92 4.01
Delays in Getting Necessary Medications
No Delays Ref. Ref. Ref.
Delays 1.06 0.71 1.58
CCI
0–1 Ref. Ref. Ref.
2–4 1.49 0.94 2.37
5+ 0.72 0.16 3.18
Number of Unique Meds 1.43 1.27 1.62
CCI = Charlson Comorbidity Index; LCGP = low cost generic program; FPL = federal poverty level;
MSA = metropolitan statistical area; Ref. = Reference category for variable.
3.3. Medication Use
From 2007–2012 the study population filled a total of 20,143 prescriptions, with 81.7% of these
prescriptions being available through LCGPs. Out of all medications available through LCGPs,
only 34.7% were actually purchased through these programs. The majority of LCGP fills were for
medications used to treat chronic conditions.
Trends in the use of LCGPs, including the proportions of LCGP fills and LCGP users in each year
as well as the total number of prescription fills per person are presented in Figure 1. Proportions of
both LCGP users and LCGP fills in each year increased significantly from 2007–2012. The proportion
of prescriptions available through LCGPs that were obtained through LCGPs more than quadrupled
from 11.0% in 2007 to 45.7% in 2012. Over the same time period, the proportion of LCGP users more
than doubled from 19.6% in 2007 to 40.7% in 2012. While the proportions of LCGP users and LCGP
fills both increased significantly from 2007–2012, overall pharmaceutical utilization remained relatively
constant with approximately 4.8 prescription fills per person per year.
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4. Discussion
Individuals living for long periods of time without insurance have the most to gain from the
affordable medications offered by LCGPs—especially so for those also suffering from chronic illness or
living below the poverty line. Results of this study indicate that the increasing use of LCGPs in the
uninsured population is not due to increasing pharmaceutical utilization but rather due to increasing
popularity and knowledge of these programs. However, despite the dramatic increase in LCGP use
amongst the uninsured, it is disconcerting that fewer than 40% of uninsured individuals in the U.S.
who use prescription medications are LCGP users. These numbers are comparable to insured adults
and lower than elderly adults with Medicare [20]. Even when only considering individuals who filled
at least one prescription available through LCGPs less than half actually filled that medication through
an LCGP.
Uninsured individuals who are living below the federal poverty threshold are disproportionately
likely to experience cost of prescription drugs as an impediment to medication access. One would
hope that individuals living below the federal poverty level would use LCGPs at a greater rate than
individuals better off financially. However, no significant differences were observed regarding the
income distribution of LCGP users and non-users and income level was not a significant predictor of
LCGP use. Taken together these results indicate that income and specifically poverty are not significant
drivers of LCGP utilization.
The self-administered questionnaire in the MEPS household component includes questions
regarding whether or not the participant experienced delays in getting necessary prescription
medications, and if so, what the cause of the delay was. Given the widespread availability and
relative affordability of LCGPs, one might expect that LCGP users would be less likely to experience
delays in obtaining necessary medications. Our study found that there is not a significant difference
between the number of LCGP users and non-users experiencing delays in obtaining prescription
medications; nor do delays in obtaining medications make individuals significantly more or less likely
to use LCGPs. Additionally, only 53.5% of individuals who reported cost of medication as the reason
for a delay in obtaining medication were classified as LCGP users. Both of these results imply that
LCGPs are not adequately being used to prevent delays in obtaining medication, particularly where
cost is a prohibitive factor.
Many state and community public health service organizations supply prescription savings
cards to uninsured individuals or include outreach programs to supply medications to the needy.
These outreach services are a tacit reflection that public health entities understand the benefits of
alleviating cost of medications as a barrier to medication access. In addition to these discount cards,
public health entities should also actively promote the use of LCGPs and attempt to improve health
literacy regarding the comparative efficacy of generic pharmaceutical products. Since many public
health organizations already maintain online instructions regarding how to obtain prescription drug
assistance, they can also include information about the widespread availability of LCGPs at little to
no cost for the organization. Furthermore, prescribers as well as major chain pharmacies should take
more of an active role in encouraging the use of LCGPs to treat common chronic and acute illnesses.
These programs are being widely used by the rest of the population [20,22] and the implications of
their use have been discussed elsewhere [11].
Given the recent expansion of Medicaid under the Affordable Care Act, many of the uninsured
individuals included in this study will now be eligible for Medicaid benefits. Although these
individuals will now receive prescription drug benefits through Medicaid plans, it is still vitally
important to encourage LCGP use in this newly insured population. Previous research has
demonstrated that individuals who are uninsured for long periods and subsequently gain insurance
will dramatically increase their healthcare utilization and spending once they become insured [23–25].
Newly insured individuals under the Affordable Care Act should be encouraged to use LCGPs to
decrease the barrier to effective pharmaceutical intervention where cost may still be a limitation even
with insurance. This also has the potential to be cost saving for state and federal payers by offsetting
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the costs of prescription medications as well as decreasing clinical sequelae of conditions which the
medications are meant to treat. Also, given the ongoing challenges to the Affordable Care Act, if it were
to be totally dismantled, it would be very beneficial for the newly uninsured population to understand
that affordable medications are available even without insurance coverage.
Our study is subject to some limitations. It may remain possible that not all medication use is
recorded if all pharmacies used were not surveyed. Our study definition of LCGP use may allow
for overestimation of use if only pricing is considered. However, this effect is mitigated by requiring
specific quantities supplied for oral medications. Our algorithm passed face validity by not detecting
medications that are not on LCGP formularies (e.g., benzodiazepines and narcotics) and also included
estimates of generic use close to other estimates using surrogate markers of medication use (e.g., 10% of
warfarin fills) [20,26]. We included a population representative of those who are uninsured for at least
two continuous years and that have filled a prescription medication. Given the data source, we cannot
verify the presence of unfilled medications in the population or account for those included in MEPS
that did not report at least one medication fill. Finally, it is possible that some individuals exclusively
use pharmacies in which LCGPs are not available and thus this population was never eligible for
inclusion in the LCGP user cohort.
5. Conclusions
A significant proportion of individuals who were uninsured for two consecutive years from
2007–2012 used an LCGP during this period. Furthermore, the proportion of LCGP users and the
proportions of LCGP fills out of all medications available through LCGPs both increased significantly
from 2007–2012. Despite the tremendous gains in the rate of LCGP use, certain subgroups including
individuals living below the poverty threshold and those experiencing delays in obtaining necessary
medications could stand to benefit from greater use of these programs. State and community public
health services should work alongside prescribers and major pharmacy chains to encourage greater
use of LCGPs among the uninsured population.
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